[go: up one dir, main page]

NO20035848L - Nye vevsfaktorrettede antistoffer som antikoagulanter - Google Patents

Nye vevsfaktorrettede antistoffer som antikoagulanter

Info

Publication number
NO20035848L
NO20035848L NO20035848A NO20035848A NO20035848L NO 20035848 L NO20035848 L NO 20035848L NO 20035848 A NO20035848 A NO 20035848A NO 20035848 A NO20035848 A NO 20035848A NO 20035848 L NO20035848 L NO 20035848L
Authority
NO
Norway
Prior art keywords
anticoagulants
tissue factor
new tissue
directed antibodies
antibodies
Prior art date
Application number
NO20035848A
Other languages
English (en)
Inventor
David R Light
Kirk Mclean
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20035848(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20035848L publication Critical patent/NO20035848L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20035848A 2002-05-01 2003-12-30 Nye vevsfaktorrettede antistoffer som antikoagulanter NO20035848L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01
PCT/US2003/013521 WO2003093422A2 (en) 2002-05-01 2003-04-30 Novel tissue factor targeted antibodies as anticoagulants

Publications (1)

Publication Number Publication Date
NO20035848L true NO20035848L (no) 2004-02-27

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20035848A NO20035848L (no) 2002-05-01 2003-12-30 Nye vevsfaktorrettede antistoffer som antikoagulanter
NO20035849A NO20035849L (no) 2002-05-01 2003-12-30 Nye vevsfaktorrettede trombomodulinfusjonsproteiner som antikoagulanter

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20035849A NO20035849L (no) 2002-05-01 2003-12-30 Nye vevsfaktorrettede trombomodulinfusjonsproteiner som antikoagulanter

Country Status (29)

Country Link
US (3) US7250168B2 (no)
EP (2) EP1503785B1 (no)
JP (2) JP4460443B2 (no)
KR (2) KR101013697B1 (no)
CN (2) CN100412090C (no)
AR (1) AR039515A1 (no)
AT (2) ATE484524T1 (no)
AU (2) AU2003225255B2 (no)
BR (2) BR0304659A (no)
CA (2) CA2483909A1 (no)
CR (1) CR7584A (no)
DE (2) DE60334538D1 (no)
DK (2) DK1549341T3 (no)
EC (2) ECSP045468A (no)
ES (2) ES2323056T3 (no)
HK (1) HK1080372A1 (no)
IL (3) IL164733A0 (no)
MX (2) MXPA04010851A (no)
NO (2) NO20035848L (no)
NZ (2) NZ536242A (no)
PE (1) PE20040597A1 (no)
PL (2) PL210582B1 (no)
PT (2) PT1549341E (no)
RS (2) RS104504A (no)
RU (2) RU2345789C2 (no)
TW (1) TWI343388B (no)
UA (2) UA85996C2 (no)
WO (2) WO2003093422A2 (no)
ZA (2) ZA200409692B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339843T3 (es) * 1999-06-02 2010-05-26 Chugai Seiyaku Kabushiki Kaisha Proteina receptora de hematopoyetina novedosa, nr10.
WO2001023556A1 (en) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
EP1330544A4 (en) 2000-09-26 2005-04-06 Univ Duke RNA APTAMERS AND METHOD OF IDENTIFYING SAID APTAMERS
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003225255B2 (en) * 2002-05-01 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted antibodies as anticoagulants
CA2490280A1 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
EP2460811A1 (en) 2004-04-22 2012-06-06 Regado Biosciences, Inc. Improved modulators of coagulation factors
CN101189334B (zh) * 2005-06-03 2013-11-06 持田制药株式会社 抗cd14抗体融合蛋白质
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
EP2007417B1 (en) * 2006-04-07 2010-10-20 Novo Nordisk Health Care AG Covalent factor vii-tissue factor complex
JP5043008B2 (ja) 2006-06-08 2012-10-10 中外製薬株式会社 炎症性疾患の予防または治療剤
MY148565A (en) * 2006-10-06 2013-04-30 Asahi Kasei Pharma Corp Agent for therapy and/or improvement of disseminated intravascular coagulation
US9649499B2 (en) * 2007-03-28 2017-05-16 Medtronic ATS Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
US20100316563A1 (en) * 2007-09-20 2010-12-16 Bracco Imaging S.P.A. Method For The Preparation Of New Oligoclonal Antibodies
WO2009072598A1 (ja) * 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 掻痒症治療剤
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
MX2011001696A (es) * 2008-08-14 2011-03-25 Merck Sharp & Dohme Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a.
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
WO2011026000A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
RU2585231C2 (ru) * 2010-06-04 2016-05-27 Ск Кемикалз Ко., Лтд. Слитый белок, обладающий активностью фактора vii
HRP20171789T1 (hr) 2010-06-15 2017-12-29 Genmab A/S Konjugati humanog protutijela s lijekom protiv tkivnog faktora
CL2011001887A1 (es) * 2010-08-05 2012-02-03 Council Scient Ind Res Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
AU2016248786B2 (en) 2015-04-14 2022-01-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient
HUE072989T2 (hu) 2015-04-14 2025-12-28 Chugai Pharmaceutical Co Ltd Gyógyszerkészítmény atópiás dermatitis megelõzésére és/vagy kezelésére, mely hatóanyagként IL-31 antagonistát tartalmaz
US10954502B2 (en) * 2015-04-28 2021-03-23 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein C activators
WO2017189943A1 (en) * 2016-04-28 2017-11-02 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
TW201831508A (zh) * 2016-11-16 2018-09-01 美商拜耳保健有限責任公司 紅血球標靶因子ｖｉｉｉ及其使用方法
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
CN112840032A (zh) * 2018-10-04 2021-05-25 血栓形成和凝血公司 用于确定蛋白水平的方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) * 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
EP0458903A4 (en) * 1989-02-17 1992-06-17 Codon Soluble analogs of thrombomodulin
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5466668A (en) * 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
KR930008093B1 (ko) * 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
EP2363484A3 (en) * 1998-04-03 2012-04-25 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003057911A2 (en) 2002-01-08 2003-07-17 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003225255B2 (en) * 2002-05-01 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
DE60334538D1 (de) 2010-11-25
CN1665534A (zh) 2005-09-07
US20080020965A1 (en) 2008-01-24
HK1080372A1 (zh) 2006-04-28
KR20050045945A (ko) 2005-05-17
IL164732A0 (en) 2005-12-18
US7250168B2 (en) 2007-07-31
JP2005532045A (ja) 2005-10-27
RU2004135308A (ru) 2005-08-10
US7622122B2 (en) 2009-11-24
DK1549341T3 (da) 2009-07-06
PE20040597A1 (es) 2004-10-06
KR20050045944A (ko) 2005-05-17
ATE427121T1 (de) 2009-04-15
CA2483909A1 (en) 2003-11-13
ATE484524T1 (de) 2010-10-15
JP4567437B2 (ja) 2010-10-20
MXPA04010795A (es) 2005-03-07
EP1549341A4 (en) 2006-10-18
CN100563709C (zh) 2009-12-02
AR039515A1 (es) 2005-02-23
WO2003093422A3 (en) 2004-07-15
IL164733A0 (en) 2005-12-18
CN100412090C (zh) 2008-08-20
PL373945A1 (en) 2005-09-19
ZA200409694B (en) 2006-02-22
RS102404A (sr) 2006-12-15
RU2345789C2 (ru) 2009-02-10
WO2003093422A2 (en) 2003-11-13
DK1503785T3 (da) 2011-02-07
RU2004135306A (ru) 2005-07-10
CA2483910A1 (en) 2003-11-13
EP1503785A4 (en) 2007-02-14
RS104504A (sr) 2007-02-05
KR101013697B1 (ko) 2011-02-10
US20080019985A1 (en) 2008-01-24
US20040063632A1 (en) 2004-04-01
US7622457B2 (en) 2009-11-24
JP2005538046A (ja) 2005-12-15
AU2003225255B2 (en) 2008-07-31
AU2003225256A1 (en) 2003-11-17
WO2003092602A3 (en) 2004-08-26
EP1503785A2 (en) 2005-02-09
ES2354419T3 (es) 2011-03-14
CN1665526A (zh) 2005-09-07
DE60326970D1 (de) 2009-05-14
TW200307043A (en) 2003-12-01
NZ536242A (en) 2006-04-28
AU2003225256B2 (en) 2009-06-04
CR7584A (es) 2006-05-30
ECSP045467A (es) 2005-01-28
MXPA04010851A (es) 2005-02-14
AU2003225255A1 (en) 2003-11-17
PL373960A1 (en) 2005-09-19
PL210582B1 (pl) 2012-02-29
JP4460443B2 (ja) 2010-05-12
ZA200409692B (en) 2006-07-26
PT1503785E (pt) 2011-01-17
BR0304659A (pt) 2004-09-21
EP1503785B1 (en) 2010-10-13
WO2003092602A2 (en) 2003-11-13
EP1549341A2 (en) 2005-07-06
ECSP045468A (es) 2005-01-28
EP1549341B1 (en) 2009-04-01
ES2323056T3 (es) 2009-07-06
PT1549341E (pt) 2009-05-29
RU2320366C2 (ru) 2008-03-27
UA81114C2 (en) 2007-12-10
NZ536243A (en) 2006-06-30
BR0304660A (pt) 2005-06-07
KR101080587B1 (ko) 2011-11-04
NO20035849L (no) 2004-02-27
TWI343388B (en) 2011-06-11
UA85996C2 (ru) 2009-03-25
IL164733A (en) 2011-05-31

Similar Documents

Publication Publication Date Title
NO20035848L (no) Nye vevsfaktorrettede antistoffer som antikoagulanter
NO20044588L (no) Nye forbindelser
NO20044432L (no) Nye forbindelser
DK1523493T3 (da) Nye tubulysinanaloge
DE50308694D1 (de) Bestrahlungsger t
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
NO20055219D0 (no) Nye forbindelser
DE60336213D1 (de) Chirurgisches klammergerät
NO20035428D0 (no) Nye anti-ineffektiver
NO20034992D0 (no) Nye 4-aninlinokinolin-3-karboksamider
NO20054005D0 (no) Nye arylpiperazinylforbindelser
EP1664117A4 (en) IMMUNOGENIC
DE50302584D1 (de) Stereomikroskop
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
DE50302514D1 (de) Stereomikroskop
DE50303208D1 (de) Osteosyntheseeinrichtung
ITPS20030026A1 (it) Struttura di osteotomo.
NO20026285D0 (no) Nye peptider
DE502004005544D1 (de) Mikrodosiereinrichtung
DE50303886D1 (de) Tragarm
NO20044098L (no) Nye forbindelser
NO20025902D0 (no) Nye fenylpiperaziner
NO20043215L (no) Nye alkansulfonamider som endothelin-antagonister
ITMI20020227A0 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
AT500592B1 (de) Entstörgerät

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application